BofA raised the firm’s price target on Axon (AXON) to $750 from $525 and keeps a Buy rating on the shares. Building on the strong refresh cycle of TASER10 and incremental AI/Software product releases, the firm sees Axon’s top-line growth continuing at over 25% from 2024-26, the analyst tells investors. Axon being the only FedRAMP certified digital evidence vendor leaves the company well positioned to the incoming administration’s priorities, the analyst added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXON:
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Axon awarded Federal Government contract to supply RCMP with cameras
- AXON Stock: Remarkable Growth, but the Valuation Poses Risk
- Axon price target raised to $585 from $387 at Barclays
- Axon price target raised to $610 from $500 at JMP Securities